Double-blind Ipragliflozin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sitagliptin (MK-0431J-843)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 143 participants.

Also called NCT02577003

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 143 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02577003
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Not reported
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02577003. Randomized; double masking; primary purpose treatment. Start 2015-11-09 (registry gives no type); primary completion 2016-11-25 (actual). Results posted on 2018-03-07.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Double-blind Ipragliflozin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sitagliptin (MK-0431J-843)
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Ipragliflozin
Intervention (Drug)
Placebo
Intervention (Drug)
Sitagliptin
Lead sponsor
Merck Sharp & Dohme LLC (class: industry)

Record details

Record id
cardio:ct-nct02577003
Content hash
a014dec4acc96e402fff47f6590025cc3171ddac93a450dabbe172d744c3e31e